C-KFDZHaya Therapeutics
RNA-guided therapies, non-coding RNA, cellular reprogramming
reprogrammingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KFDZ
C-KFDZC-KFDZRNA-guided therapies, non-coding RNA, cellular reprogramming
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Haya Therapeutics RNA-guided therapies, non-coding RNA, cellular reprogramming
HAYA Therapeutics develops programmable RNA medicines designed to reprogram disease-driving cell states. Its platform integrates multimodal functional genomics with proprietary computational tools to decode the regulatory genome and identify non-coding RNAs that causally drive disease. The company lists operations in Lausanne, Switzerland and San Diego, California.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Haya Therapeutics — Early mechanism · Lower middle. Derived deterministically from 9 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical).…
Source: Deterministic